Posted by Michael Wonder on 26 Jan 2023
Syros receives fast track designation from the FDA for tamibarotene for the treatment of higher-risk myelodysplastic syndrome
26 January 2023 - Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression.
Syros Pharmaceuticals today announced that the US FDA has granted fast track designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome.
